2020 update of the eular recommendations for the

Submit Demands Online

2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis Affiliations 1 Rheumatology and Clinical Immunology Unit Attikon University Hospital Athens Greece Exactly 3 months later the guidelines were presented at the EULAR 2020 virtual congress on 3 rd June 2020 PROVISIONAL RECOMMENDATIONS Musculos keletal disease guidelines in the context of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as outlined by EULAR is "an unprecedented set of recommendations " according to Prof Landew

EULAR updates management recommendations for

An update will be needed within 2–4 years as new data arise in PsA For further reference log on to: Gossec L Baraliakos X Kerschbaumer A et al EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

A EULAR task force developed recommendations for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy • Management of irAEs should be based on a shared decision-making process between patients

2020/2/13Smolen JS Landew RBM Bijlsma JWJ et al EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [published online January 22 2020] Ann Rheum Dis doi:10

1 Ann Rheum Dis 2020 Jan 79(1):61-68 doi: 10 1136/annrheumdis-2019-215458 Epub 2019 Jul 12 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis Bech B(1) Primdahl J(2)(3) van Tubergen

Smolen JS Landew RB Bijlsma JWJ et al EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [published online January 22 2020] Ann Rheum Dis doi: 10

EULAR Updates Guidelines for Large Vessel Vasculitis

The European League Against Rheumatism (EULAR) has updated treatment guidelines for the management of large vessel vasculitis (LVV) The guidelines which were last updated in 2008 incorporate findings from the results of newly published randomized clinical

Objectives To analyse the current evidence for the management of large vessel vasculitis (LVV) to inform the 2018 update of the EULAR recommendations Methods Two systematic literature reviews (SLRs) dealing with diagnosis/monitoring and treatment strategies for LVV respectively were performed Medline Embase and Cochrane databases were searched from inception to 31 December 2017

Objectives: To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field Methods: An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature

Objective: To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) Methods: According to the EULAR standardised operating procedures a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019

2020/6/1Objectives To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field Methods An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic

Background: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009 several relevant randomised clinical trials and cohort analyses have been published which have the potential to change clinical care and therefore supporting the need to update the original recommendations

Objectives: To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field Methods: An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature

medwireNews: EULAR has issued updated recommendations for the pharmacologic management of psoriatic arthritis (PsA) "These recommendations have been modified substantially compared with the 2015 update " say Laure Gossec (Sorbonne Universite Paris

Update of EULAR recommendations for the Management of SLE

Jan 2020 1 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Antonis Fanouriakis1* Myrto Kostopoulou2 Alessia Alunno3 Martin Aringer4 Ingeborg Bajema5 John N Boletis6 Ricard Cervera7 Andrea Doria8

Title EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Published in Annals of the rheumatic diseases 79(6) S700 - S712 BMJ Publishing Group ISSN 0003-4967 Author Gossec Laure Baraliakos

To update the European League Against Rheumatism (EULAR) recommendations for the role of the nurse in the management of chronic inflammatory arthritis (CIA) using the most up to date evidence The EULAR standardised operating procedures were followed A

The EULAR Task Force developed a total of four overarching principles and 10 recommendations which have now been published in Annals of the Rheumatic Diseases (Kostine M et al Ann Rheum Dis 2020) The major challenge remains to relieve patient symptoms without altering the oncological outcome and a focus on shared decision-making is paramount Dr Benesova stressed

Smolen JS Landew RB Bijlsma JWJ et al EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [published online January 22 2020] Ann Rheum Dis doi: 10

Jan 2020 1 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Antonis Fanouriakis1* Myrto Kostopoulou2 Alessia Alunno3 Martin Aringer4 Ingeborg Bajema5 John N Boletis6 Ricard Cervera7 Andrea Doria8

Jan 2020 1 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Antonis Fanouriakis1* Myrto Kostopoulou2 Alessia Alunno3 Martin Aringer4 Ingeborg Bajema5 John N Boletis6 Ricard Cervera7 Andrea Doria8

Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) Methods According to the EULAR standardised operating procedures a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019 Levels of evidence and strengths of